BIOGEN

Biopharmaceutical innovation policy issues and supply chain International intellectual property and market access policy issues Trade-related aspects of Intellectual Property (TRIPS) Waiver General outbound investment policy issues

Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number

Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act

Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) American Innovations and Jobs Act issues related to OECD negotiations on the taxation of global income

Issues related to the 340B program reforms